Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FAM AB on the acquisition of Sandvik Process Systems
Mandate

Vinge advises FAM AB on the acquisition of Sandvik Process Systems

June 02, 2017 M&A Carve-Outs

Vinge advises FAM AB on the acquisition of Sandvik Process Systems (”SPS”) from Sandvik AB at a price of approximately SEK 5 bn.

Sandvik Process Systems delivers advanced industrial process solutions based on high-end steel belts, steel belt based equipment and process solutions within adjacent technologies. The transaction is subject to competition clearance.

Vinge’s team includes responsible partner Jonas Johansson and counsel Matthias Pannier together with partners Eva Fredrikson and Assur Badur, counsel Johan Cederblad and associates Karl Klackenberg, Mathilda Persson, Johanna Wiberg, Sara Strandberg, Sofia Ekdahl, Grant McKelvey, Johan Wahlbom, Isabell Nielsen, Rebecka Weitzberg, Karin Virding, Linn Adelwald, Carolina Sandell, Jasmin Draszka-Ali, Hedvig Ekdahl, Olof Johannesson, Siri Dunér as well as VDR specialist Anna Hellohf.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026